Emerging viral infections

Clinics in Laboratory Medicine

Volumn 24, Issue 3, 2004, Pages 773-795

  Su, John R ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR 7; CIDOFOVIR; IMMUNOGLOBULIN; RIBAVIRIN; STEROID;

CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; EPIDEMIC; FATALITY; FILOVIRUS; GENE MUTATION; GEOGRAPHY; HANTAVIRUS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN METAPNEUMOVIRUS; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INCIDENCE; INCUBATION TIME; INFLUENZA VIRUS; MONKEYPOX; OUTCOMES RESEARCH; POXVIRUS; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SMALLPOX; SMALLPOX VIRUS; SYMPTOM; VIRAL GENETICS; VIRUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

COMMUNICABLE DISEASES, EMERGING; HUMANS; VIRUS DISEASES;

EID: 8444234225     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.05.002     Document Type: Review

References (211)

1. Morse S.S. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1:(1):1995;7-15
2. Emerging infections: microbial threats to health in the United States. 1992;National Academy Press, Washington, DC
3. Darbyshire J., Foulkes M., Peto R., Duncan W., Babiker A., Collins R., et al. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. Cochrane Database Syst Rev. 3:2000;. CD002039
4. Yu H., Jetzt A.E., Ron Y., Preston B.D., Dougherty J.P. The nature of human immunodeficiency virus type 1 strand transfers. J Biol Chem. 273:(43):1998;28384-28391
5. Ammaranond P., Cunningham P., Oelrichs R., Suzuki K., Harris C., Leas L., et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol. 26:(2):2003;153-161
6. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 69:(8):1995;5087-5094
7. Sabin C.A. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS. 16:(Suppl 4):2002;S61-S68
8. Harrigan P.R., Montaner J.S., Wegner S.A., Verbiest W., Miller V., Wood R., et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS. 15:(13):2001;1671-1677
9. International AIDS Society-USA Resistance Testing Panel. Antiretroviral resistance mutations [revised April 2001]. HIV Clin Trials. 2:(4):2001;346-355
10. Blaise P., Clevenbergh P., Vaira D., Moutschen M., Dellamonica P. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg. 57:(4):2002;191-201
11. Lafeuillade A., Poggi C., Hittinger G., Chadapaud S. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Med. 2:(4):2001;231-235
12. Yeni P.G., Hammer S.M., Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 288:(2):2002;222-235
13. Hirsch M.S., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 37:(1):2003;113-128
14. Cingolani A., Antinori A., Rizzo M.G., Murri R., Ammassari A., Baldini F., et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 16:(3):2002;369-379
15. Cohen C.J., Hunt S., Sension M., Farthing C., Conant M., Jacobson S., et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 16:(4):2002;579-588
16. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 353:(9171):1999;2195-2199
17. Arthur R.R. Ebola in Africa - discoveries in the past decade. Euro Surveill. 7:(3):2002;33-36
18. Peters C.J., LeDuc J.W. An introduction to Ebola: the virus and the disease. J Infect Dis. 179:(Suppl 1):1999;ix-xvi
19. Le Guenno B., Formentry P., Wyers M., Gounon P., Walker F., Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 345:(8960):1995;1271-1274
20. Turell M.J., Bressler D.S., Rossi C.A. Short report: lack of virus replication in arthropods after intrathoracic inoculation of Ebola Reston virus. Am J Trop Med Hyg. 55:(1):1996;89-90
21. Reiter P., Turell M., Coleman R., Miller B., Maupin G., Liz J., et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis. 179:(Suppl 1):1999;S148-S154
22. Geisbert T.W., Hensley L.E., Jahrling P.B., Larsen T., Geisbert J.B., Paragas J., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 362:(9400):2003;1953-1958
23. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:(10):2001;699-709
24. Taylor F.B. Jr., Wada H., Kinasewitz G. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: toward a better definition of DIC. Crit Care Med. 28:(Suppl 9):2000;S12-S19
25. Fisher C.J. Jr., Yan S.B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 28:(Suppl 9):2000;S49-S56
26. Gilligan K.J., Geisbert J.B., Jarhling P.B., Anderson K.A. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. Brown F., Burton D., Norrby E., Mekalanos J., Doherty P. Vaccines '97. 1997;87-92 Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY)
27. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246:(1):1998;134-144
28. Xu L., Sanchez A., Yang Z., Zaki S.R., Nabel E.G., Nichol S.T., et al. Immunization for Ebola virus infection. Nat Med. 4:(1):1998;37-42
29. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 424:(6949):2003;681-684
30. Bray M., Driscoll J., Huggins J.W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 45:(2):2000;135-147
31. Huggins J., Zhang Z.X., Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis. 179:(Suppl 1):1999;S240-S247
32. Leroy E.M., Baize S., Lu C.Y., McCormick J.B., Georges A.J., Georges-Courbot M.C., et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol. 60:(4):2000;463-467
33. Ksiazek T.G., West C.P., Rollin P.E., Jahrling P.B., Peters C.J. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis. 179:(Suppl 1):1999;S192-S198
34. Niikura M., Ikegami T., Saijo M., Kurane I., Miranda M.E., Morikawa S. Detection of Ebola viral antigen by enzyme-linked immunosorbent assay using a novel monoclonal antibody to nucleoprotein. J Clin Microbiol. 39:(9):2001;3267-3271
35. Sanchez A., Ksiazek T.G., Rollin P.E., Miranda M.E., Trappier S.G., Khan A.S., et al. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J Infect Dis. 179:(Suppl 1):1999;S164-S169
36. Jezek Z., Szczeniowski M.Y., Muyembe-Tamfum J.J., McCormick J.B., Heymann D.L. Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981-1985. J Infect Dis. 179:(Suppl 1):1999;S60-S64
37. Bray M. Defense against filoviruses used as biological weapons. Antiviral Res. 57:(1-2):2003;53-60
38. Alibek K., Handelman S. Biohazard: the chilling true story of the largest covert biological weapons program in the world - told from inside by the man who ran it. 1999;Random House, New York
39. Lee H.W., Lee P.W., Johnson K.M. Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis. 137:(3):1978;298-308
40. Chapman L.E., Khabbaz R.F. Etiology and epidemiology of the Four Corners hantavirus outbreak. Infect Agents Dis. 3:(5):1994;234-244
41. Hjelle B., Torrez-Martinez N., Koster F.T., Jay M., Ascher M.S., Brown T., et al. Epidemiologic linkage of rodent and human hantavirus genomic sequences in case investigations of hantavirus pulmonary syndrome. J Infect Dis. 173:(4):1996;781-786
42. Nemirov K., Lundkvist A., Vaheri A., Plyusnin A. Adaptation of Puumala hantavirus to cell culture is associated with point mutations in the coding region of the L segment and in the noncoding regions of the S segment. J Virol. 77:(16):2003;8793-8800
43. Plyusnin A., Cheng Y., Lehvaslaiho H., Vaheri A. Quasispecies in wild-type tula hantavirus populations. J Virol. 70:(12):1996;9060-9063
44. Henderson W.W., Monroe M.C., St Jeor S.C., Thayer W.P., Rowe J.E., Peters C.J., et al. Naturally occurring Sin Nombre virus genetic reassortants. Virology. 214:(2):1995;602-610
45. Klempa B., Schmidt H.A., Ulrich R., Kaluz S., Labuda M., Meisel H., et al. Genetic interaction between distinct Dobrava hantavirus subtypes in Apodemus agrarius and A. flavicollis in nature. J Virol. 77:(1):2003;804-809
46. Sibold C., Meisel H., Kruger D.H., Labuda M., Lysy J., Kozuch O., et al. Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. J Virol. 73:(1):1999;667-675
47. Glass G.E., Johnson J.S., Hodenbach G.A., Disalvo C.L., Peters C.J., Childs J.E., et al. Experimental evaluation of rodent exclusion methods to reduce hantavirus transmission to humans in rural housing. Am J Trop Med Hyg. 56:(4):1997;359-364
48. Plyusnin A. Genetics of hantaviruses: implications to taxonomy. Arch Virol. 147:(4):2002;665-682
49. Lednicky J.A. Hantaviruses. a short review. Arch Pathol Lab Med. 127:(1):2003;30-35
50. Peters C.J., Simpson G.L., Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 50:1999;531-545
51. Howard M.J., Doyle T.J., Koster F.T., Zaki S.R., Khan A.S., Petersen E.A., et al. Hantavirus pulmonary syndrome in pregnancy. Clin Infect Dis. 29:(6):1999;1538-1544
52. Lloyd G., Jones N. Infection of laboratory workers with hantavirus acquired from immunocytomas propagated in laboratory rats. J Infect Dis. 12:(2):1986;117-125
53. Prebensen D. Nephropathia Epidemica infection during first trimester of pregnancy - normal fetal outcome. Acta Obstet Gynecol Scand. 76:(9):1997;884-885
54. Toro J., Vega J.D., Khan A.S., Mills J.N., Padula P., Terry W., et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis. 4:(4):1998;687-694
55. Padula P.J., Edelstein A., Miguel S.D., Lopez N.M., Rossi C.M., Rabinovich R.D. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology. 241:(2):1998;323-330
56. Peters C.J., Khan A.S. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin Infect Dis. 34:(9):2002;1224-1231
57. Huggins J.W., Hsiang C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 164:(6):1991;1119-1127
58. Graziano K.L., Tempest B. Hantavirus pulmonary syndrome: a zebra worth knowing. Am Fam Physician. 66:(6):2002;1015-1020
59. Ferres M., Vial P. Hantavirus infection in children. Curr Opin Pediatr. 16:(1):2004;70-75
60. Chapman L.E., Mertz G.J., Peters C.J., Jolson H.M., Khan A.S., Ksiazek T.G., et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther. 4:(4):1999;211-219
61. Gavrilovskaya I.N., Shepley M., Shaw R., Ginsberg M.H., Mackow E.R. Beta3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A. 95:(12):1998;7074-7079
62. Mackow E.R., Gavrilovskaya I.N. Cellular receptors and hantavirus pathogenesis. Curr Top Microbiol Immunol. 256:2001;91-115
63. Mori M., Rothman A.L., Kurane I., Montoya J.M., Nolte K.B., Norman J.E., et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis. 179:(2):1999;295-302
64. Ennis F.A., Cruz J., Spiropoulou C.F., Waite D., Peters C.J., Nichol S.T., et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology. 238:(2):1997;380-390
65. Wimer B.M. Implications of the analogy between recombinant cytokine toxicities and manifestations of hantavirus infections. Cancer Biother Radiopharm. 13:(3):1998;193-207
66. Padula P.J., Colavecchia S.B., Martinez V.P., Gonzalez Della Valle M.O., Edelstein A., Miguel S.D., et al. Genetic diversity, distribution, and serological features of hantavirus infection in five countries in South America. J Clin Microbiol. 38:(8):2000;3029-3035
67. Elgh F., Lundkvist A., Alexeyev O.A., Stenlund H., Avsic-Zupanc T., Hjelle B., et al. Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes. J Clin Microbiol. 35:(5):1997;1122-1130
68. Lundkvist A., Cheng Y., Sjolander K.B., Niklasson B., Vaheri A., Plyusnin A. Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment. J Virol. 71:(12):1997;9515-9523
69. Murray K., Selleck P., Hooper P., Hyatt A., Gould A., Gleeson L., et al. A morbillivirus that caused fatal disease in horses and humans. Science. 268:(5207):1995;94-97
70. Chua K.B., Bellini W.J., Rota P.A., Harcourt B.H., Tamin A., Lam S.K., et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 288:(5470):2000;1432-1435
71. Wang L., Harcourt B.H., Yu M., Tamin A., Rota P.A., Bellini W.J., et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect. 3:(4):2001;279-287
72. Selvey L.A., Wells R.M., McCormack J.G., Ansford A.J., Murray K., Rogers R.J., et al. Infection of humans and horses by a newly described morbillivirus. Med J Aust. 162:(12):1995;642-645
73. O'Sullivan J.D., Allworth A.M., Paterson D.L., Snow T.M., Boots R., Gleeson L.J., et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet. 349:(9045):1997;93-95
74. Hooper P., Zaki S., Daniels P., Middleton D. Comparative pathology of the diseases caused by Hendra and Nipah viruses. Microbes Infect. 3:(4):2001;315-322
75. Field H., Young P., Yob J.M., Mills J., Hall L., Mackenzie J. The natural history of Hendra and Nipah viruses. Microbes Infect. 3:(4):2001;307-314
76. Chua K.B., Goh K.J., Wong K.T., Kamarulzaman A., Tan P.S., Ksiazek T.G., et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet. 354:(9186):1999;1257-1259
77. Goh K.J., Tan C.T., Chew N.K., Tan P.S., Kamarulzaman A., Sarji S.A., et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med. 342:(17):2000;1229-1235
78. Tan C.T., Goh K.J., Wong K.T., Sarji S.A., Chua K.B., Chew N.K., et al. Relapsed and late-onset Nipah encephalitis. Ann Neurol. 51:(6):2002;703-708
79. Enserink M. Emerging infectious diseases. Nipah virus (or a cousin) strikes again. Science. 303:(5661):2004;1121
80. Daniels P., Ksiazek T., Eaton B.T. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect. 3:(4):2001;289-295
81. Lam S.K. Nipah virus - a potential agent of bioterrorism? Antiviral Res. 57:(1-2):2003;113-119
82. Centers for Disease Control. Bioterrorism agents/diseases. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp. Accessed March 23, 2004.
83. Chong H.T., Kamarulzaman A., Tan C.T., Goh K.J., Thayaparan T., Kunjapan S.R., et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol. 49:(6):2001;810-813
84. Guillaume V., Contamin H., Loth P., Georges-Courbot M.C., Lefeuvre A., Marianneau P., et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol. 78:(2):2004;834-840
85. van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 7:(6):2001;719-724
86. Ebihara T., Endo R., Kikuta H., Ishiguro N., Ishiko H., Kobayashi K. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol. 72:(2):2004;304-306
87. Maggi F., Pifferi M., Vatteroni M., Fornai C., Tempestini E., Anzilotti S., et al. Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy. J Clin Microbiol. 41:(7):2003;2987-2991
88. Stockton J., Stephenson I., Fleming D., Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis. 8:(9):2002;897-901
89. Cuevas L.E., Nasser A.M., Dove W., Gurgel R.Q., Greensill J., Hart C.A. Human metapneumovirus and respiratory syncytial virus. Brazil. Emerg Infect Dis. 9:(12):2003;1626-1628
90. Viazov S., Ratjen F., Scheidhauer R., Fiedler M., Roggendorf M. High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. J Clin Microbiol. 41:(7):2003;3043-3045
91. Chan P.K., Tam J.S., Lam C.W., Chan E., Wu A., Li C.K., et al. Human metapneumovirus detection in patients with severe acute respiratory syndrome. Emerg Infect Dis. 9:(9):2003;1058-1063
92. Greensill J., McNamara P.S., Dove W., Flanagan B., Smyth R.L., Hart C.A. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis. 9:(3):2003;372-375
93. Falsey A.R., Erdman D., Anderson L.J., Walsh E.E. Human metapneumovirus infections in young and elderly adults. J Infect Dis. 187:(5):2003;785-790
94. Williams J.V., Harris P.A., Tollefson S.J., Halburnt-Rush L.L., Pingsterhaus J.M., Edwards K.M., et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 350:(5):2004;443-450
95. Boivin G., Abed Y., Pelletier G., Ruel L., Moisan D., Cote S., et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. 186:(9):2002;1330-1334
96. Boivin G., De Serres G., Cote S., Gilca R., Abed Y., Rochette L., et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis. 9:(6):2003;634-640
97. Maertzdorf J., Wang C.K., Brown J.B., Quinto J.D., Chu M., De Graaf M., et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol. 42:(3):2004;981-986
98. Guan Y., Peiris J.S., Lipatov A.S., Ellis T.M., Dyrting K.C., Krauss S., et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci U S A. 99:(13):2002;8950-8955
99. Alexander D.J. Report on avian influenza in the Eastern Hemisphere during 1997-2002. Avian Dis. 47:(Suppl 3):2003;792-797
100. Smirnov Y.A., Gitelman A.K., Govorkova E.A., Lipatov A.S., Kaverin N.V. Influenza H5 virus escape mutants: immune protection and antibody production in mice. Virus Res. 99:(2):2004;205-208
101. Cases of influenza A (H5N1) - Thailand, 2004. MMWR Morb Mortal Wkly Rep. 53:(5):2004;100-103
102. Outbreaks of avian influenza A (H5N1) in Asia and interim recommendations for evaluation and reporting of suspected cases - United States, 2004. MMWR Morb Mortal Wkly Rep. 53:(5):2004;97-100
103. Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 101:(5):2004;1356-1361
104. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 363:(9409):2004;587-593
105. Banks J., Plowright L. Additional glycosylation at the receptor binding site of the hemagglutinin (HA) for H5 and H7 viruses may be an adaptation to poultry hosts, but does it influence pathogenicity? Avian Dis. 47:(Suppl 3):2003;942-950
106. Senne D.A., Suarez D.L., Pedersen J.C., Panigrahy B. Molecular and biological characteristics of H5 and H7 avian influenza viruses in live-bird markets of the northeastern United States, 1994-2001. Avian Dis. 47:(Suppl 3):2003;898-904
107. Spackman E., Senne D.A., Davison S., Suarez D.L. Sequence analysis of recent H7 avian influenza viruses associated with three different outbreaks in commercial poultry in the United States. J Virol. 77:(24):2003;13399-13402
108. Webby R.J., Woolcock P.R., Krauss S.L., Walker D.B., Chin P.S., Shortridge K.F., et al. Multiple genotypes of nonpathogenic H6N2 influenza viruses isolated from chickens in California. Avian Dis. 47:(Suppl 3):2003;905-910
109. Cameron K.R., Gregory V., Banks J., Brown I.H., Alexander D.J., Hay A.J., et al. H9N2 subtype influenza A viruses in poultry in Pakistan are closely related to the H9N2 viruses responsible for human infection in Hong Kong. Virology. 278:(1):2000;36-41
110. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet. 354:(9182):1999;916-917
111. Peiris J.S., Guan Y., Markwell D., Ghose P., Webster R.G., Shortridge K.F. Cocirculation of avian H9N2 and contemporary "human" H3N2 influenza A viruses in pigs in southeastern China: potential for genetic reassortment? J Virol. 75:(20):2001;9679-9686
112. Li K.S., Xu K.M., Peiris J.S., Poon L.L., Yu K.Z., Yuen K.Y., et al. Characterization of H9 subtype influenza viruses from the ducks of southern China: a candidate for the next influenza pandemic in humans? J Virol. 77:(12):2003;6988-6994
113. Tumpey T.M., Garcia-Sastre A., Taubenberger J.K., Palese P., Swayne D.E., Basler C.F. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A. 101:(9):2004;3166-3171
114. Ladnyj I.D., Ziegler P., Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 46:(5):1972;593-597
115. von Magnus P., Anderson E.K., Petersen K.B., Birch-Anderson A. A pox-like disease in cynomolgus monkeys. Acta Pathol Microbiol Scand. 46:1959;156-176
116. Update: multistate outbreak of monkeypox - Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 52:(27):2003;642-646
117. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 350:(4):2004;342-350
118. Jezek Z., Szczeniowski M., Paluku K.M., Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 156:(2):1987;293-298
119. Breman J.G., Henderson D.A. Diagnosis and management of smallpox. N Engl J Med. 346:(17):2002;1300-1308
120. Breman J.G., Kalisa R., Steniowski M.V., Zanotto E., Gromyko A.I., Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 58:(2):1980;165-182
121. Hanrahan J.A., Jakubowycz M., Davis B.R. A smallpox false alarm. N Engl J Med. 348:(5):2003;467-468. [discussion: 467-8]
122. Breman J.G. Monkeypox: an emerging infection for humans? Scheld W.M., Craig W.A., Hughes J.M. Emerging infections. 4th edition :2000;45-67 ASM Press, Washington, DC
123. Damon I.K., Esposito J.J. Poxviruses that infect humans. Murray P.R., Baron E.J., Jorgensen J.H., Pfaller M.A., Yolker M.H. Manual of clinical microbiology. 8th edition :2003;1583-1591 ASM Press, Washington, DC
124. Espy M.J., Cockerill I.F., Meyer R.F., Bowen M.D., Poland G.A., Hadfield T.L., et al. Detection of smallpox virus DNA by LightCycler PCR. J Clin Microbiol. 40:(6):2002;1985-1988
125. Laassri M., Chizhikov V., Mikheev M., Shchelkunov S., Chumakov K. Detection and discrimination of orthopoxviruses using microarrays of immobilized oligonucleotides. J Virol Methods. 112:(1-2):2003;67-78
126. Lapa S., Mikheev M., Shchelkunov S., Mikhailovich V., Sobolev A., Blinov V., et al. Species-level identification of orthopoxviruses with an oligonucleotide microchip. J Clin Microbiol. 40:(3):2002;753-757
127. Di Giulio D.B., Eckburg P.B. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 4:(1):2004;15-25
128. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55:(1):2002;1-13
129. Heymann D.L., Szczeniowski M., Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 54:(3):1998;693-702
130. Zaucha G.M., Jahrling P.B., Geisbert T.W., Swearengen J.R., Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest. 81:(12):2001;1581-1600
131. Gubser C., Hue S., Kellam P., Smith G.L. Poxvirus genomes: a phylogenetic analysis. J Gen Virol. 85:(Pt 1):2004;105-117
132. Shchelkunov S.N., Totmenin A.V., Safronov P.F., Mikheev M.V., Gutorov V.V., Ryazankina O.I., et al. Analysis of the monkeypox virus genome. Virology. 297:(2):2002;172-194
133. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol. 75:(3):2001;1205-1210
134. Stich A., Meyer H., Kohler B., Fleischer K. Tanapox: first report in a European traveller and identification by PCR. Trans R Soc Trop Med Hyg. 96:(2):2002;178-179
135. Dhar A.D., Werchniak A.E., Li Y., Brennick J.B., Goldsmith C.S., Kline R., et al. Tanapox infection in a college student. N Engl J Med. 350:(4):2004;361-366
136. Baxby D., Bennett M. Poxvirus zoonoses. J Med Microbiol. 46:(1):1997;17-20. 28-33
137. Diven D.G. An overview of poxviruses. J Am Acad Dermatol. 44:(1):2001;1-16
138. Knight J.C., Novembre F.J., Brown D.R., Goldsmith C.S., Esposito J.J. Studies on Tanapox virus. Virology. 172:(1):1989;116-124
139. Brunetti C.R., Amano H., Ueda Y., et al. Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol. 77:(24):2003;13335-13347
140. Lee H.J., Essani K., Smith G.L. The genome sequence of Yaba-like disease virus, a yatapoxvirus. Virology. 281:(2):2001;170-192
141. Downie A.W., Espana C. Comparison of Tanapox virus and Yaba-like viruses causing epidemic disease in monkeys. J Hyg (Lond). 70:(1):1972;23-32
142. McNulty W.P. Jr., Lobitz W.C. Jr., Hu F., Maruffo C.A., Hall A.S. A pox disease in monkeys transmitted to man. Clinical and histological features. Arch Dermatol. 97:(3):1968;286-293
143. Henderson D., Moss B. Smallpox and vaccinia. Plotkin S., Orenstein S., Zorab R. Vaccines. 3rd edition :1999;74-97 Harcourt Brace and Co., Philadelphia
144. Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol Rev. 24:(2):2000;123-133
145. Keith K.A., Hitchcock M.J., Lee W.A., Holy A., Kern E.R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob Agents Chemother. 47:(7):2003;2193-2198
146. Breman J.G., Henderson D.A. Poxvirus dilemmas - monkeypox, smallpox, and biologic terrorism. N Engl J Med. 339:(8):1998;556-559
147. Bonilla-Guerrero R., Poland G.A. Smallpox vaccines: current and future. J Lab Clin Med. 142:(4):2003;252-257
148. Clements C.J. Mass psychogenic illness after vaccination. Drug Saf. 26:(9):2003;599-604
149. Cardiac deaths after a mass smallpox vaccination campaign - New York City. MMWR Morb Mortal Wkly Rep 2003. 52:(39):1947;933-936
150. Gellman B. 4 nations thought to possess smallpox. Washington Post, November 5, 2002.
151. Nitsche A., Ellerbrok H., Pauli G. Detection of orthopoxvirus DNA by real-time PCR and identification of variola virus DNA by melting analysis. J Clin Microbiol. 42:(3):2004;1207-1213
152. Sofi Ibrahim M., Kulesh D.A., Saleh S.S., Damon I.K., Esposito J.J., Schmaljohn A.L., et al. Real-time PCR assay to detect smallpox virus. J Clin Microbiol. 41:(8):2003;3835-3839
153. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science. 300:(5624):2003;1399-1404
154. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with Severe Acute Respiratory Syndrome. N Engl J Med. 348:(20):2003;1953-1966
155. Peiris J.S., Yuen K.Y., Osterhaus A.D., Stohr K. The Severe Acute Respiratory Syndrome. N Engl J Med. 349:(25):2003;2431-2441
156. Monto A.S., Lim S.K. The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection. J Infect Dis. 129:(3):1974;271-276
157. Parry J. WHO confirms SARS in Chinese journalist. BMJ. 328:(7431):2004;65
158. Stavrinides J., Guttman D.S. Mosaic evolution of the Severe Acute Respiratory Syndrome coronavirus. J Virol. 78:(1):2004;76-82
159. Guan Y., Peiris J., Zheng B., Poon L., Chan K., Zeng F., et al. Molecular epidemiology of the novel coronavirus that causes Severe Acute Respiratory Syndrome. Lancet. 363:(9403):2004;99-104
160. Severe Acute Respiratory Syndrome - Singapore. MMWR Morb Mortal Wkly Rep. 2003. 52:(18):2003;405-411
161. Riley S., Fraser C., Donnelly C.A., Ghani A.C., Abu-Raddad L.J., Hedley A.J., et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science. 300:(5627):2003;1961-1966
162. Grant P.R., Garson J.A., Tedder R.S., Chan P.K., Tam J.S., Sung J.J. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med. 349:(25):2003;2468-2469
163. Ng L.F., Wong M., Koh S., Ooi E.E., Tang K.F., Leong H.N., et al. Detection of Severe Acute Respiratory Syndrome coronavirus in blood of infected patients. J Clin Microbiol. 42:(1):2004;347-350
164. Lee N., Hui D., Wu A., Chan P., Cameron P., Joynt G.M., et al. A major outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med. 348:(20):2003;1986-1994
165. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 289:(21):2003;2801-2809
166. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., et al. A cluster of cases of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med. 348:(20):2003;1977-1985
167. Fujii T., Nakamura T., Iwamoto A. Current concepts in SARS treatment. J Infect Chemother. 10:(1):2004;1-7
168. Jones B.M., Ma E.S., Peiris J.S., Wong P.C., Ho J.C., Lam B., et al. Prolonged disturbances of in vitro cytokine production in patients with Severe Acute Respiratory Syndrome (SARS) treated with ribavirin and steroids. Clin Exp Immunol. 135:(3):2004;467-473
169. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 59:(3):2004;252-256
170. World Health Organization issues emergency travel advisory. March 15, 2003.
171. Tang P., Louie M., Richardson S.E., Smieja M., Simor A.E., Jamieson F., et al. Interpretation of diagnostic laboratory tests for Severe Acute Respiratory Syndrome: the Toronto experience. CMAJ. 170:(1):2004;47-54
172. Poon L.L., Chan K.H., Wong O.K., Cheung T.K., Ng I., Zheng B., et al. Detection of SARS coronavirus in patients with Severe Acute Respiratory Syndrome by conventional and real-time quantitative reverse transcription-PCR assays. Clin Chem. 50:(1):2004;67-72
173. Yam W.C., Chan K.H., Poon L.L., Guan Y., Yuen K.Y., Seto W.H., et al. Evaluation of reverse transcription-PCR assays for rapid diagnosis of Severe Acute Respiratory Syndrome associated with a novel coronavirus. J Clin Microbiol. 41:(10):2003;4521-4524
174. WHO post-outbreak biosafety guidelines for handling of SARS-CoV specimens and cultures. December 18, 2003.
175. Enserink M. Infectious diseases. Singapore lab faulted in SARS case. Science. 301:(5641):2003;1824
176. Normile D. Infectious diseases. Second lab accident fuels fears about SARS. Science. 303:(5654):2004;26
177. Smithburn K.C., Hughes T.P., Burke A.W., Paul J.H. Neurotropic virus isolated from blood of native of Uganda. Am J Trop Med. 20:1940;471-492
178. Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc. 78:(9):2003;1137-1143. [quiz: 1144]
179. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 286:(5448):1999;2333-2337
180. Turell M.J., Sardelis M.R., Dohm D.J., O'Guinn M.L. Potential North American vectors of West Nile virus. Ann N Y Acad Sci. 951:2001;317-324
181. Campbell G.L., Marfin A.A., Lanciotti R.S., Gubler D.J. West Nile virus. Lancet Infect Dis. 2:(9):2002;519-529
182. Marfin A.A., Petersen L.R., Eidson M., Miller J., Hadler J., Farello C., et al. Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis. 7:(4):2001;730-735
183. Malkinson M., Banet C., Weisman Y., Pokamunski S., King R., Drouet M.T., et al. Introduction of West Nile virus in the Middle East by migrating white storks. Emerg Infect Dis. 8:(4):2002;392-397
184. Update: investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion - Michigan, 2002. MMWR Morb Mortal Wkly Rep. 51:(39):2002;879
185. Centers for Disease Control and Prevention. Laboratory-acquired West Nile virus infections - United States, 2002. JAMA. 289:(4):2003;414-415
186. Feldmann H., Jones S., Klenk H.D., Schnittler H.J. Ebola virus: from discovery to vaccine. Nat Rev Immunol. 3:(8):2003;677-685
187. Centers for Disease Control and Prevention. Investigations of West Nile virus infections in recipients of blood transfusions. JAMA. 288:(20):2002;2535- 2536
188. Centers for Disease Control and Prevention. Possible West Nile virus transmission to an infant through breast-feeding - Michigan, 2002. JAMA. 288:(16):2002;1976-1977
189. Centers for Disease Control and Prevention. West Nile virus activity - United States, September 26-October 2, 2002, and investigations of West Nile virus infections in recipients of blood transfusion and organ transplantation. JAMA. 288:(16):2002;1975-1976
190. Iwamoto M., Jernigan D.B., Guasch A., Trepka M.J., Blackmore C.G., Hellinger W.C., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 348:(22):2003;2196-2203
191. Detection of West Nile virus in blood donations - United States, 2003. MMWR Morb Mortal Wkly Rep. 52:(32):2003;769-772
192. Harrington T., Kuehnert M.J., Kamel H., Lanciotti R.S., Hand S., Currier M., et al. West Nile virus infection transmitted by blood transfusion. Transfusion. 43:(8):2003;1018-1022
193. Spigland I., Jasinska-Klingberg W., Hofshi E., Goldblum N. Clinical and laboratory observations in an outbreak of West Nile fever in Israel in 1957. Harefuah. 54:(11):1958;275-280. [English and French abstracts: 280-1]
194. Asnis D.S., Conetta R., Teixeira A.A., Waldman G., Sampson B.A. The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis. 30:(3):2000;413-418
195. Petersen L.R., Marfin A.A. West Nile virus: a primer for the clinician. Ann Intern Med. 137:(3):2002;173-179
196. Klein C., Kimiagar I., Pollak L., Gandelman-Marton R., Itzhaki A., Milo R., et al. Neurological features of West Nile virus infection during the 2000 outbreak in a regional hospital in Israel. J Neurol Sci. 200:(1-2):2002;63-66
197. Weiss D., Carr D., Kellachan J., Tan C., Phillips M., Bresnitz E., et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis. 7:(4):2001;654-658
198. Chowers M.Y., Lang R., Nassar F., Ben-David D., Giladi M., Rubinshtein E., et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 7:(4):2001;675-678
199. Nash D, Labowitz A, Maldin B, et al. A follow-up study of persons infected with West Nile virus during a 1999 outbreak in the New York City area [abstract]. Presented at the 39th Annual Meetings of the Infectious Diseases Society of America. San Francisco, 2001.
200. Deubel V., Fiette L., Gounon P., Drouet M.T., Khun H., Huerre M., et al. Variations in biological features of West Nile viruses. Ann N Y Acad Sci. 951:2001;195-206
201. Brinton M.A. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol. 56:2002;371-402
202. Sampson B.A., Armbrustmacher V. West Nile encephalitis: the neuropathology of four fatalities. Ann N Y Acad Sci. 951:2001;172-178
203. Cantile C., Del Piero F., Di Guardo G., Arispici M. Pathologic and immunohistochemical findings in naturally occuring West Nile virus infection in horses. Vet Pathol. 38:(4):2001;414-421
204. Steele K.E., Linn M.J., Schoepp R.J., Komar N., Geisbert T.W., Manduca R.M., et al. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol. 37:(3):2000;208-224
205. Sampson B.A., Nields H., Armbrustmacher V., Asnis D.S. Muscle weakness in West Nile encephalitis is due to destruction of motor neurons. Hum Pathol. 34:(6):2003;628-629
206. Tardei G., Ruta S., Chitu V., Rossi C., Tsai T.F., Cernescu C. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. J Clin Microbiol. 38:(6):2000;2232-2239
207. Lanciotti R.S., Kerst A.J., Nasci R.S., Godsey M.S., Mitchell C.J., Savage H.M., et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol. 38:(11):2000;4066-4071
208. Shimoni Z., Niven M.J., Pitlick S., Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis. 7:(4):2001;759
209. Jordan I., Briese T., Fischer N., Lau J.Y., Lipkin W.I. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis. 182:(4):2000;1214-1217
210. Anderson J.F., Rahal J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis. 8:(1):2002;107-108
211. Nipah virus in Bangladesh. WHO Disease Outbreak News. April 20, 2004. Available at: http://www.who.int/csr/don/2004_04_20/en/Accessed on June 17, 2004.